<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775706</url>
  </required_header>
  <id_info>
    <org_study_id>HM-GLP2-201</org_study_id>
    <secondary_id>DOLPHINS-2</secondary_id>
    <nct_id>NCT04775706</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects</brief_title>
  <official_title>A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study&#xD;
      to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with&#xD;
      SBS-associated intestinal failure (SBS-IF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a screening period, a run-in period, a 6-months core treatment period,&#xD;
      a 7-months extension treatment period and a safety follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>for 24 weeks</time_frame>
    <description>after multiple subcutaneous (SC) doses</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>HM15912 0.5 mg/kg Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM15912 Active</intervention_name>
    <description>Randomized, double-blind, placebo-controlled</description>
    <arm_group_label>HM15912 0.5 mg/kg Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomized, double-blind, placebo-controlled</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women, aged 18 years of age or older with intestinal failure resulting in SBS&#xD;
             at the time of signing the informed consent form (ICF) (or country's legal age of&#xD;
             majority if the legal age is &lt;18 years)&#xD;
&#xD;
          2. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in this protocol&#xD;
&#xD;
          3. Diagnosis of SBS defined as remaining small bowel in continuity of estimated &lt;200 cm&#xD;
             (equal to 79 inches) and with the latest intestinal resection being at least 6 months&#xD;
             prior to Screening and considered stable regarding the PN/IV need. No restorative&#xD;
             surgery planned in the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of colon cancer.&#xD;
&#xD;
          2. History of any other cancers (except margin-free resected cutaneous basal or squamous&#xD;
             cell carcinoma or adequately treated in situ cervical cancer) unless disease-free for&#xD;
             at least 5 years&#xD;
&#xD;
          3. History of alcohol or drug abuse (within 1 year of screening)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunkyoung Oh</last_name>
    <phone>+82 2 410 0370</phone>
    <email>eunkyoung.oh@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Iyer Kishore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Washington</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Subramanian Sukanya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Joly-Gomez Francisca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Maasberg Sebastian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Fusco Stefano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <state>Poznan</state>
        <zip>60-780</zip>
        <country>Poland</country>
      </address>
    </facility>
    <investigator>
      <last_name>Matysiak Konrad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medicome Sp. z o.o.</name>
      <address>
        <city>Oświęcim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mroziak Beata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

